The companies in line for the biggest gains — and the shareholders who have already made fortunes. The arrival of Covid vaccines promises a return to more normal life — and has created a global market worth tens of billions of dollars in annual sales for some pharmaceutical companies.
Whether the market remains a money-spinner in the future depends on whether the vaccines become the type that need just a one-off shot — as for measles — or if regular vaccinations will be required, such as for flu. But in the immediate future, there are big financial returns up for grabs. Here, we look at who is in line for the biggest gains — and which shareholders have already made fortunes.
It was the first to be approved and has to be stored at ultra-low temperatures C. The final number could be twice as high, as Pfizer says it can potentially deliver 2bn doses this year. The vaccine produced by the US biotech firm, based in Massachusetts, must be stored at freezer temperature C. The UK has ordered 17m doses, the EU bought m with an option for a further m in , while the US government ordered m shots.
Japan purchased 50m shots. A group of investors that backed the company when it was founded in will have made substantial returns.
It uses adenovirus, a rare variant of cold virus. It was approved in the US in late February and can be stored at standard fridge temperatures for at least three months. In addition, the segment includes a research and development unit and a contract manufacturing business. As you might expect, the innovative health segment generates more revenue than the essential health segment does.
What might be surprising, though, is that the essential health segment actually claims a higher profit margin than innovative health does. Where is the most money made within the biggest moneymaking segment? The category that generates the highest revenue is the company's internal medicine drugs. Pfizer's internal medicine category includes three of the company's nine blockbuster drugs.
However, Pfizer is experiencing even greater sales growth with cancer drugs Ibrance and Xtandi, as well as rheumatoid arthritis drug Xeljanz. The top-selling internal medicine drug is Lyrica. An older formulation of Lyrica is also marketed by the essential health segment.
However, Pfizer's biggest blockbuster isn't Lyrica. That honor goes to Prevnar Three other drugs could potentially come close to that level down the road. Bavencio, which recently won approval for treating metastatic Merkel cell carcinoma, might even surpass Prevnar's sales level if the drug is successful in additional indications. Investors should be as interested in where Pfizer's money goes as they are in where its money comes from.
A significant amount was spent last year on acquisitions. The company picked up Xtandi with the former deal and atopic dermatitis drug Eucrisa with the latter deal. With a current yield of 3. You could look at all of this spending in another way.
Food and Drug Administration. Centers for Disease Control and Prevention. Company Profiles. Fundamental Analysis. Tech Stocks. Your Privacy Rights. To change or withdraw your consent choices for Investopedia. At any time, you can update your settings through the "EU Privacy" link at the bottom of any page.
These choices will be signaled globally to our partners and will not affect browsing data. We and our partners process data to: Actively scan device characteristics for identification. I Accept Show Purposes. Your Money. Personal Finance. Your Practice.
Popular Courses. Business Company Profiles. Key Takeaways Pfizer develops and manufactures drug treatments to promote health and prevent disease. The company's oncology products generate the most revenue, but revenue from its rare disease treatments is growing the fastest. Article Sources. Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate.
You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy. Compare Accounts. The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear.
0コメント